2023
A systematic review and meta-analysis of neuromodulation therapies for substance use disorders
Mehta D, Praecht A, Ward H, Sanches M, Sorkhou M, Tang V, Steele V, Hanlon C, George T. A systematic review and meta-analysis of neuromodulation therapies for substance use disorders. Neuropsychopharmacology 2023, 49: 649-680. PMID: 38086901, PMCID: PMC10876556, DOI: 10.1038/s41386-023-01776-0.Peer-Reviewed Original ResearchRepetitive transcranial magnetic stimulationTranscranial direct current stimulationSubstance use disordersDeep brain stimulationDorsolateral prefrontal cortexUse disordersEffects of rTMSTreatment of SUDsSubstance useLong-term outcomesLeft dorsolateral prefrontal cortexTranscranial magnetic stimulationSystematic literature searchDirect current stimulationEffect sizeSubstance use outcomesAddiction neurocircuitryUncontrolled studiesDBS studiesNeuromodulation therapiesMagnetic stimulationPsychosocial treatmentsBrain stimulationTreatment durationAdministration protocol
2022
Mechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders
Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. Mechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders. Current Behavioral Neuroscience Reports 2022, 9: 124-143. DOI: 10.1007/s40473-022-00250-3.Peer-Reviewed Original ResearchSubstance use disordersN-acetylcysteineUse disordersEfficacy of NACTreatment of SUDsGlial glutamate transporter-1Glutamate transporter 1Drug-seeking behaviorCue-induced reinstatementNAC useAdjunctive useClinical studiesGlutamate homeostasisGlutamate signalingNeurobiological effectsClinical approachRelapse behaviorSubcortical regionsSynaptic plasticityFunctional connectivity networksPrefrontal cortexBehavioral interventionsTransporter 1Oxidative stressImpulsive behavior
2020
Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders
Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders. JAMA Network Open 2020, 3: e208279. PMID: 32558914, PMCID: PMC7305524, DOI: 10.1001/jamanetworkopen.2020.8279.Peer-Reviewed Original ResearchConceptsSubstance use disordersAdult alcohol use disordersCognitive behavioral therapyUsual careRandomized clinical trialsUse disordersBehavioral therapySpecific therapyClinical trialsAddition of CBTSuperiority of CBTTreatment of SUDsUsual clinical managementForms of pharmacotherapyFirst-line interventionEvidence-based therapiesClinical trial samplesEvidence-based modalitiesAlcohol use disorderEnglish-language articlesPublic health concernFull-text articlesEffect sizeCochrane RegisterRandom effects estimates
2018
Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review
Peltier MR, Sofuoglu M. Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review. CNS Drugs 2018, 32: 421-435. PMID: 29761343, PMCID: PMC6235727, DOI: 10.1007/s40263-018-0525-5.Peer-Reviewed Original ResearchConceptsSubstance use disordersExogenous progesteroneUse disordersTreatment of SUDsNovel pharmacological treatmentsFemale sex hormonesTreatment of menNovel pharmacological interventionsTobacco/nicotineFemale substance usersDrugs of abuseMetabolite allopregnanolonePharmacological treatmentPreliminary efficacySex hormonesPharmacological interventionsAvailable interventionsNovel treatmentsAllopregnanoloneEuphoric effectsProgesteroneNarrative reviewLiterature searchSubstance useSubstance usersCentral and Peripheral Biomarkers of Stress Response for Addiction Risk and Relapse Vulnerability
Milivojevic V, Sinha R. Central and Peripheral Biomarkers of Stress Response for Addiction Risk and Relapse Vulnerability. Trends In Molecular Medicine 2018, 24: 173-186. PMID: 29396148, PMCID: PMC6511993, DOI: 10.1016/j.molmed.2017.12.010.Peer-Reviewed Original ResearchConceptsSubstance use disordersTreatment of SUDsDevelopment of SUDHigh relapse rateFunctional brain alterationsCentral stress responseAdrenal axis markersStress response measuresRelapse ratePeripheral biomarkersClinical symptomatologyBrain alterationsUse disordersCandidate biomarkersAutonomic responsesRelapse vulnerabilityPutative biomarkersAddiction riskStress responseBiomarkersTreatmentResponsePathophysiologySymptomatologyPrevention
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply